Operating Income: The income after operating expenses.
Apimeds Pharmaceuticals US, Inc. (APUS) had Operating Income of $-0.36M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.40M |
|
-- |
|
-- |
|
$0.36M |
|
|
Operating Income |
$-0.36M |
$-0.04M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.40M |
|
$-0.36M |
|
$-0.36M |
|
7.90M |
|
7.90M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$0.26M |
|
-- |
|
-- |
|
$0.26M |
|
$1.77M |
|
$0.25M |
|
$0.25M |
|
$2.02M |
|
$-1.76M |
|
$-1.76M |
|
$-1.76M |
|
7.90M |
|
| Cash Flow Statement Financials | |
$-0.02M |
|
-- |
|
$0.27M |
|
$0.00M |
|
$0.25M |
|
$0.25M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.15 |
|
-- |
|
-- |
|
-0.17 |
|
-0.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.02M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
22.86% |
|
22.86% |
|
-154.83% |
|
26.64% |
|
$-0.22 |
|
$-0.00 |
|
$-0.00 |
|